Molbio Diagnostics 
Dealstreet

Khaitan & Co, Cyril Amarchand Mangaldas, Hogan Lovells Cadwalader act on Molbio Diagnostics ₹939 crore IPO

The proceeds of the IPO will be channeled towards a R&D facility, Centre of Excellence and office infrastructure; a plant, machinery and equipment for manufacturing units; and general corporate purposes

Bar & Bench

Molbio Diagnostics Limited has raised ₹939.696 crore from an initial public offering of equity shares, comprised of a fresh issue and an offer for sale.

Khaitan & Co advised Molbio Diagnostics on this IPO.

The transaction team consisted of Abhimanyu Bhattacharya (Partner), Gautham Srinivas (Partner), Sathvik Ponnappa (Partner), Sanjeev Chowdhary (Principal Associate), Vaishnavi Gupta (Senior Associate), Mainak Pani (Associate) and Shambhavi Gautam (Associate).

Abhimanyu Bhattacharya, Gautham Srinivas, Sathvik Ponnappa

Cyril Amarchand Mangaldas advised the book-running lead managers Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited, on this IPO.

The transaction was led by Yash J. Ashar (Senior Partner) and Priyadarshini Rao (Partner), with assistance from Raksha Raina (Senior Associate), Associates Prakhar Jain, Janhavi Deshmukh, Zubin Ronnie, Aria Sheth and Namita Kaushik.

Yash Ashar, Priyadarshini Rao

Hogan Lovells Cadwalader acted as International Counsel for the lead managers.

The transaction team was led by Biswajit Chatterjee (Head of the India Practice and Dubai Office Managing Partner).

Biswajit Chatterjee

Molbio is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid, and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. Their flagship innovation, Truenat, is a novel POC polymerase chain reaction (PCR) platform that is battery-operated and can operate in resource-limited settings, facilitating decentralized diagnosis within an hour.

The IPO was subscribed 70.26 times, with the portion reserved for qualified institutional buyers being subscribed 186.39 times.

The proceeds of the IPO will be channeled towards a R&D facility, Centre of Excellence and office infrastructure; a plant, machinery and equipment for manufacturing units; and general corporate purposes

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Independent directors: A protective mechanism or a false sense of security?

Lenders and borrowers: Ad-hoc is out; institutional ODR is in

Social media handle not licence to post anything: Karnataka High Court

DNLU, Jabalpur to host ‘JUSTECH’ National Conclave on the ‘Role of AI, Technology in Access to Justice’

Sanjeev Kumar Sharma joins White & Brief as National Head – Litigation & Dispute Resolution

SCROLL FOR NEXT